HRP20191348T1 - Aminosteroidi za liječenje bolesti povezanih s ptp1b - Google Patents

Aminosteroidi za liječenje bolesti povezanih s ptp1b Download PDF

Info

Publication number
HRP20191348T1
HRP20191348T1 HRP20191348TT HRP20191348T HRP20191348T1 HR P20191348 T1 HRP20191348 T1 HR P20191348T1 HR P20191348T T HRP20191348T T HR P20191348TT HR P20191348 T HRP20191348 T HR P20191348T HR P20191348 T1 HRP20191348 T1 HR P20191348T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
treatment
tyrosine
Prior art date
Application number
HRP20191348TT
Other languages
English (en)
Inventor
Michael Mclane
Inez Ruiz-White
W. Lee Maloy
Henry R. Wolfe
Original Assignee
Ohr Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohr Pharmaceutical, Inc. filed Critical Ohr Pharmaceutical, Inc.
Publication of HRP20191348T1 publication Critical patent/HRP20191348T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (16)

1. Spoj ili njegova farmaceutski prihvatljiva sol izabrana u grupi koja se sastoji od:
2. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
3. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
4. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
5. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
6. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
7. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
8. Farmaceutski spoj koji sadrži spoj iz bilo kojeg od zahtjeva od 1 do 7 i farmaceutski prihvatljiv razrjeđivač ili nosač.
9. Spoj sukladno zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
10. Spoj sukladno zahtjevu 2 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
11. Spoj sukladno zahtjevu 3 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
12. Spoj sukladno zahtjevu 4 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
13. Spoj sukladno zahtjevu 5 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
14. Spoj sukladno zahtjevu 6 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
15. Spoj sukladno zahtjevu 7 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
16. Spoj za uporabu sukladno bilo kojem od zahtjeva od 9 do 15, gdje je poremećaj izabran iz grupe koja se sastoji od dijabetesa, pretilosti i visokog kolesterola.
HRP20191348TT 2012-04-20 2019-07-25 Aminosteroidi za liječenje bolesti povezanih s ptp1b HRP20191348T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636252P 2012-04-20 2012-04-20
EP13721176.9A EP2838907B1 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease
PCT/US2013/037330 WO2013158970A2 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease

Publications (1)

Publication Number Publication Date
HRP20191348T1 true HRP20191348T1 (hr) 2019-10-18

Family

ID=48325893

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191348TT HRP20191348T1 (hr) 2012-04-20 2019-07-25 Aminosteroidi za liječenje bolesti povezanih s ptp1b

Country Status (16)

Country Link
US (5) US9546194B2 (hr)
EP (2) EP2838907B1 (hr)
JP (4) JP6165843B2 (hr)
KR (3) KR20150003798A (hr)
AU (3) AU2013249111B2 (hr)
CA (1) CA2870671C (hr)
DK (1) DK2838907T3 (hr)
ES (1) ES2736310T3 (hr)
HK (1) HK1205516A1 (hr)
HR (1) HRP20191348T1 (hr)
HU (1) HUE044769T2 (hr)
MX (2) MX367255B (hr)
PL (1) PL2838907T3 (hr)
PT (1) PT2838907T (hr)
TR (1) TR201911039T4 (hr)
WO (1) WO2013158970A2 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201911039T4 (tr) * 2012-04-20 2019-08-21 Ohr Pharmaceutical Inc Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
WO2019050903A1 (en) * 2017-09-08 2019-03-14 Enterin Laboratories, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
CN107802626B (zh) * 2017-10-11 2020-01-21 南昌大学 降血糖组合物及其制备方法、用途
CN111801102B (zh) * 2017-11-06 2024-05-28 冷泉港实验室 用于形成含铜络合物的方法和组合物及其用途
AU2019242557A1 (en) * 2018-03-27 2020-10-15 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
CA3110049A1 (en) * 2018-07-20 2020-01-23 Cold Spring Harbor Laboratory (pyridinylmethyl)butanediamine derivatives that chelate copper
EP4007765A4 (en) * 2019-08-02 2023-08-23 Enterin, Inc. HUMAN SQUALAMIN DERIVATIVES, COMPOSITIONS CONTAINING THEM, AND METHODS OF USE THEREOF
CA3149479A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
WO2023230593A1 (en) 2022-05-27 2023-11-30 Cold Spring Harbor Laboratory Ptp1b inhibitors for treating lung injury

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US3636210A (en) * 1968-02-02 1972-01-18 Merck & Co Inc Cholanic acid and cholenic acid compositions and method of treatment
JPS60181096A (ja) * 1984-02-28 1985-09-14 Tokyo Tanabe Co Ltd 胆汁酸の精製方法
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
AU6392894A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
CA2157594A1 (en) 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
CA2223910C (en) * 1995-06-07 2008-09-16 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
AU7476800A (en) 1999-09-10 2001-04-10 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
AU6985300A (en) 1999-09-10 2001-04-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
JP2003509429A (ja) 1999-09-10 2003-03-11 ノボ ノルディスク アクティーゼルスカブ タンパク質チロシンホスファターゼ(ptpアーゼ)のモジュレーター
US7074778B2 (en) * 1999-12-09 2006-07-11 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
ATE433457T1 (de) * 2002-12-24 2009-06-15 Univ British Columbia Angiogen-wirkende trisulfat steroide und deren verwendung
JP2006165843A (ja) * 2004-12-06 2006-06-22 Matsushita Electric Ind Co Ltd 画像処理装置
US20080058300A1 (en) 2006-04-21 2008-03-06 Mclane Michael Induction of weight loss and the selective inhibition of PTP1B
CA2985271A1 (en) * 2007-09-06 2009-03-12 Ohr Pharmaceutical, Inc. A method for treating diabetes
KR101260221B1 (ko) * 2011-12-01 2013-05-06 주식회사 엘지화학 마스크
TR201911039T4 (tr) 2012-04-20 2019-08-21 Ohr Pharmaceutical Inc Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.

Also Published As

Publication number Publication date
KR20190034685A (ko) 2019-04-02
AU2013249111B2 (en) 2018-08-09
MX367255B (es) 2019-08-12
KR20150003798A (ko) 2015-01-09
JP2017178951A (ja) 2017-10-05
MX2014012619A (es) 2015-01-15
US9546194B2 (en) 2017-01-17
EP3556765B1 (en) 2022-02-23
US20200270300A1 (en) 2020-08-27
CA2870671C (en) 2020-05-12
PL2838907T3 (pl) 2019-12-31
KR20160091435A (ko) 2016-08-02
JP6165843B2 (ja) 2017-07-19
ES2736310T3 (es) 2019-12-27
KR102057812B1 (ko) 2019-12-19
JP6457010B2 (ja) 2019-01-23
AU2020203736A1 (en) 2020-06-25
US20170129914A1 (en) 2017-05-11
WO2013158970A3 (en) 2013-12-12
EP2838907A2 (en) 2015-02-25
US20230203088A1 (en) 2023-06-29
KR101963312B1 (ko) 2019-03-28
US20190202858A1 (en) 2019-07-04
EP2838907B1 (en) 2019-05-22
PT2838907T (pt) 2019-08-05
AU2013249111A1 (en) 2014-11-06
WO2013158970A2 (en) 2013-10-24
TR201911039T4 (tr) 2019-08-21
EP3556765A1 (en) 2019-10-23
MX2019009539A (es) 2019-09-26
AU2020203736B2 (en) 2021-12-02
JP2015514781A (ja) 2015-05-21
US10556923B2 (en) 2020-02-11
US11434257B2 (en) 2022-09-06
AU2018256561A1 (en) 2018-11-22
HK1205516A1 (en) 2015-12-18
JP2019059781A (ja) 2019-04-18
AU2018256561B2 (en) 2020-03-05
CA2870671A1 (en) 2013-10-24
JP2021073250A (ja) 2021-05-13
DK2838907T3 (da) 2019-08-05
US20150099727A1 (en) 2015-04-09
HUE044769T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
HRP20191348T1 (hr) Aminosteroidi za liječenje bolesti povezanih s ptp1b
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2012107034A5 (hr)
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
BR112014026285A2 (pt) oligonucleotídeos moduladores de rna com características melhoradas para o tratamento de distúrbios neuromusculares
JP2014513036A5 (hr)
JP2015504870A5 (hr)
JP2013181136A5 (ja) ポリイミド前駆体組成物、ポリイミド成形体、及び画像形成装置
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
JP2013523758A5 (hr)
BR112014016127A2 (pt) sistemas espiroesteroidais com efeitos neuroativos e anti-inflamatórios, e, composição farmacêutica
SMT201600334B (it) Interferone beta per l'uso nel trattamento della malattia del tratto respiratorio inferiore causata da influenza
JP2013059750A5 (hr)
TH1501003557A (th) "การใช้ของ 3-คาร์บอกซี-N-เอทิล-N,N-ไดเมทิลโพรพาน-1-อะมิเนียม หรือเกลือที่ยอมรับได้ทางเภสัชกรรมของสารนี้ในการรักษาของโรคหลอดเลือดแดงแข็ง(atherosclerosis)"
TH133140S (th) เก้าอี้
TH119602B (th) ลวดลายจาน
TH38935S1 (th) ลวดลายจาน
TH38000S1 (th) ลวดลายจาน
TH38002S1 (th) ลวดลายจาน
TH126855S (th) ลวดลายจาน
TH123434S (th) ลวดลายจาน
TH112398A (th) องค์ประกอบทางเภสัชกรรมสำหรับโรคพาร์กินสัน
TH155756S (th) แผ่นปูพื้น
TH155757S (th) แผ่นปูพื้น
TH60013S1 (th) แผ่นปูพื้น